#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Epilepsy is a disorder in the central nervous system ( CNS ) that is characterized by an increase in the number of electrical impulses that occurs in one focal locus of the brain and/or the entire brain , resulting in partial or generalized seizures .
3-1	17-25	Epilepsy	abstract	new	coref	3-3[4_0]
3-2	26-28	is	_	_	_	_
3-3	29-30	a	abstract[4]	giv[4]	coref	7-3[0_4]
3-4	31-39	disorder	abstract[4]	giv[4]	_	_
3-5	40-42	in	abstract[4]	giv[4]	_	_
3-6	43-46	the	abstract[4]|abstract[5]	giv[4]|new[5]	appos	3-11[0_5]
3-7	47-54	central	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
3-8	55-62	nervous	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
3-9	63-69	system	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
3-10	70-71	(	_	_	_	_
3-11	72-75	CNS	abstract	giv	_	_
3-12	76-77	)	_	_	_	_
3-13	78-82	that	_	_	_	_
3-14	83-85	is	_	_	_	_
3-15	86-99	characterized	_	_	_	_
3-16	100-102	by	_	_	_	_
3-17	103-105	an	event[7]	new[7]	_	_
3-18	106-114	increase	event[7]	new[7]	_	_
3-19	115-117	in	event[7]	new[7]	_	_
3-20	118-121	the	event[7]|abstract[8]	new[7]|new[8]	_	_
3-21	122-128	number	event[7]|abstract[8]	new[7]|new[8]	_	_
3-22	129-131	of	event[7]|abstract[8]	new[7]|new[8]	_	_
3-23	132-142	electrical	event[7]|abstract[8]|abstract[9]	new[7]|new[8]|new[9]	_	_
3-24	143-151	impulses	event[7]|abstract[8]|abstract[9]	new[7]|new[8]|new[9]	_	_
3-25	152-156	that	_	_	_	_
3-26	157-163	occurs	_	_	_	_
3-27	164-166	in	_	_	_	_
3-28	167-170	one	place[10]	new[10]	_	_
3-29	171-176	focal	place[10]	new[10]	_	_
3-30	177-182	locus	place[10]	new[10]	_	_
3-31	183-185	of	place[10]	new[10]	_	_
3-32	186-189	the	place[10]|object[11]	new[10]|new[11]	_	_
3-33	190-195	brain	place[10]|object[11]	new[10]|new[11]	_	_
3-34	196-202	and/or	place[10]|object[11]	new[10]|new[11]	_	_
3-35	203-206	the	place[10]|object[11]|object[12]	new[10]|new[11]|new[12]	coref	6-12[0_12]
3-36	207-213	entire	place[10]|object[11]|object[12]	new[10]|new[11]|new[12]	_	_
3-37	214-219	brain	place[10]|object[11]|object[12]	new[10]|new[11]|new[12]	_	_
3-38	220-221	,	_	_	_	_
3-39	222-231	resulting	_	_	_	_
3-40	232-234	in	_	_	_	_
3-41	235-242	partial	event[13]	new[13]	coref	6-5[25_13]
3-42	243-245	or	event[13]	new[13]	_	_
3-43	246-257	generalized	event[13]	new[13]	_	_
3-44	258-266	seizures	event[13]	new[13]	_	_
3-45	267-268	.	_	_	_	_

#Text=The administration of antiepileptic drugs is mostly done via the oral or intravenous routes .
4-1	269-272	The	event[14]	new[14]	coref	12-21[0_14]
4-2	273-287	administration	event[14]	new[14]	_	_
4-3	288-290	of	event[14]	new[14]	_	_
4-4	291-304	antiepileptic	event[14]|substance|substance[16]	new[14]|new|new[16]	coref|coref	8-1[0_16]|8-1[0_16]
4-5	305-310	drugs	event[14]|substance[16]	new[14]|new[16]	_	_
4-6	311-313	is	_	_	_	_
4-7	314-320	mostly	_	_	_	_
4-8	321-325	done	_	_	_	_
4-9	326-329	via	_	_	_	_
4-10	330-333	the	place[17]	new[17]	_	_
4-11	334-338	oral	place[17]	new[17]	_	_
4-12	339-341	or	place[17]	new[17]	_	_
4-13	342-353	intravenous	place[17]	new[17]	_	_
4-14	354-360	routes	place[17]	new[17]	_	_
4-15	361-362	.	_	_	_	_

#Text=Drug resistance at the late stage of therapy develops in about 40 % of patients .
5-1	363-367	Drug	substance|abstract[19]	new|new[19]	coref|coref|coref|coref	6-1[24_19]|8-22|6-1[24_19]|8-22
5-2	368-378	resistance	abstract[19]	new[19]	_	_
5-3	379-381	at	abstract[19]	new[19]	_	_
5-4	382-385	the	abstract[19]|abstract[20]	new[19]|new[20]	_	_
5-5	386-390	late	abstract[19]|abstract[20]	new[19]|new[20]	_	_
5-6	391-396	stage	abstract[19]|abstract[20]	new[19]|new[20]	_	_
5-7	397-399	of	abstract[19]|abstract[20]	new[19]|new[20]	_	_
5-8	400-407	therapy	abstract[19]|abstract[20]|event	new[19]|new[20]|new	_	_
5-9	408-416	develops	_	_	_	_
5-10	417-419	in	_	_	_	_
5-11	420-425	about	quantity[22]	new[22]	_	_
5-12	426-428	40	quantity[22]	new[22]	_	_
5-13	429-430	%	quantity[22]	new[22]	_	_
5-14	431-433	of	quantity[22]	new[22]	_	_
5-15	434-442	patients	quantity[22]|person	new[22]|new	coref	7-1[30_0]
5-16	443-444	.	_	_	_	_

#Text=Drug resistance leads to uncontrolled seizures , a higher risk of brain damage , and increased mortality rates .
6-1	445-449	Drug	abstract[24]	giv[24]	coref	8-22[45_24]
6-2	450-460	resistance	abstract[24]	giv[24]	_	_
6-3	461-466	leads	_	_	_	_
6-4	467-469	to	_	_	_	_
6-5	470-482	uncontrolled	event[25]	giv[25]	coref	7-11[0_25]
6-6	483-491	seizures	event[25]	giv[25]	_	_
6-7	492-493	,	_	_	_	_
6-8	494-495	a	abstract[26]	new[26]	_	_
6-9	496-502	higher	abstract[26]	new[26]	_	_
6-10	503-507	risk	abstract[26]	new[26]	_	_
6-11	508-510	of	abstract[26]	new[26]	_	_
6-12	511-516	brain	abstract[26]|object|abstract[28]	new[26]|giv|new[28]	coref|coref	9-19|9-19
6-13	517-523	damage	abstract[26]|abstract[28]	new[26]|new[28]	_	_
6-14	524-525	,	_	_	_	_
6-15	526-529	and	_	_	_	_
6-16	530-539	increased	_	_	_	_
6-17	540-549	mortality	abstract[29]	new[29]	_	_
6-18	550-555	rates	abstract[29]	new[29]	_	_
6-19	556-557	.	_	_	_	_

#Text=Patients with epilepsy suffer from emotional and behavioral changes , seizures , convulsions , muscular spasms , depression and , in some cases , unconsciousness .
7-1	558-566	Patients	person[30]	giv[30]	_	_
7-2	567-571	with	person[30]	giv[30]	_	_
7-3	572-580	epilepsy	person[30]|abstract	giv[30]|giv	coref	8-7
7-4	581-587	suffer	_	_	_	_
7-5	588-592	from	_	_	_	_
7-6	593-602	emotional	abstract[32]	new[32]	_	_
7-7	603-606	and	abstract[32]	new[32]	_	_
7-8	607-617	behavioral	abstract[32]	new[32]	_	_
7-9	618-625	changes	abstract[32]	new[32]	_	_
7-10	626-627	,	_	_	_	_
7-11	628-636	seizures	event	giv	_	_
7-12	637-638	,	_	_	_	_
7-13	639-650	convulsions	abstract	new	_	_
7-14	651-652	,	_	_	_	_
7-15	653-661	muscular	abstract[35]	new[35]	_	_
7-16	662-668	spasms	abstract[35]	new[35]	_	_
7-17	669-670	,	_	_	_	_
7-18	671-681	depression	abstract	new	_	_
7-19	682-685	and	_	_	_	_
7-20	686-687	,	_	_	_	_
7-21	688-690	in	_	_	_	_
7-22	691-695	some	abstract[37]	new[37]	_	_
7-23	696-701	cases	abstract[37]	new[37]	_	_
7-24	702-703	,	_	_	_	_
7-25	704-719	unconsciousness	_	_	_	_
7-26	720-721	.	_	_	_	_

#Text=Drugs used for the treatment of epilepsy have poor bioavailability and eventually become ineffective over the course of treatment due to drug resistance .
8-1	722-727	Drugs	substance	giv	coref	10-6[58_0]
8-2	728-732	used	_	_	_	_
8-3	733-736	for	_	_	_	_
8-4	737-740	the	event[39]	new[39]	coref	8-19[43_39]
8-5	741-750	treatment	event[39]	new[39]	_	_
8-6	751-753	of	event[39]	new[39]	_	_
8-7	754-762	epilepsy	event[39]|abstract	new[39]|giv	coref	9-1
8-8	763-767	have	_	_	_	_
8-9	768-772	poor	substance[41]	new[41]	coref	12-1[74_41]
8-10	773-788	bioavailability	substance[41]	new[41]	_	_
8-11	789-792	and	_	_	_	_
8-12	793-803	eventually	_	_	_	_
8-13	804-810	become	_	_	_	_
8-14	811-822	ineffective	_	_	_	_
8-15	823-827	over	_	_	_	_
8-16	828-831	the	event[42]	new[42]	_	_
8-17	832-838	course	event[42]	new[42]	_	_
8-18	839-841	of	event[42]	new[42]	_	_
8-19	842-851	treatment	event[42]|event[43]	new[42]|giv[43]	coref	9-1[47_43]
8-20	852-855	due	event[42]|event[43]	new[42]|giv[43]	_	_
8-21	856-858	to	_	_	_	_
8-22	859-863	drug	substance|abstract[45]	giv|giv[45]	coref|coref	9-12[49_0]|9-12[49_0]
8-23	864-874	resistance	abstract[45]	giv[45]	_	_
8-24	875-876	.	_	_	_	_

#Text=Epilepsy treatment is often complicated due to the poor release of the drug through the adjunctive blood – brain barrier , which may be overcome by the preparation of the drug as solid lipid nanoparticles .
9-1	877-885	Epilepsy	abstract|event[47]	giv|giv[47]	coref|coref	18-16|18-16
9-2	886-895	treatment	event[47]	giv[47]	_	_
9-3	896-898	is	_	_	_	_
9-4	899-904	often	_	_	_	_
9-5	905-916	complicated	_	_	_	_
9-6	917-920	due	_	_	_	_
9-7	921-923	to	_	_	_	_
9-8	924-927	the	event[48]	new[48]	coref	10-13[61_48]
9-9	928-932	poor	event[48]	new[48]	_	_
9-10	933-940	release	event[48]	new[48]	_	_
9-11	941-943	of	event[48]	new[48]	_	_
9-12	944-947	the	event[48]|substance[49]	new[48]|giv[49]	coref	9-30[54_49]
9-13	948-952	drug	event[48]|substance[49]	new[48]|giv[49]	_	_
9-14	953-960	through	event[48]	new[48]	_	_
9-15	961-964	the	event[48]|substance[50]	new[48]|new[50]	_	_
9-16	965-975	adjunctive	event[48]|substance[50]	new[48]|new[50]	_	_
9-17	976-981	blood	event[48]|substance[50]	new[48]|new[50]	_	_
9-18	982-983	–	_	_	_	_
9-19	984-989	brain	object|object[52]	giv|new[52]	coref|coref	10-22[63_0]|10-22[63_0]
9-20	990-997	barrier	object[52]	new[52]	_	_
9-21	998-999	,	_	_	_	_
9-22	1000-1005	which	_	_	_	_
9-23	1006-1009	may	_	_	_	_
9-24	1010-1012	be	_	_	_	_
9-25	1013-1021	overcome	_	_	_	_
9-26	1022-1024	by	_	_	_	_
9-27	1025-1028	the	abstract[53]	new[53]	_	_
9-28	1029-1040	preparation	abstract[53]	new[53]	_	_
9-29	1041-1043	of	abstract[53]	new[53]	_	_
9-30	1044-1047	the	abstract[53]|substance[54]	new[53]|giv[54]	coref	10-16[0_54]
9-31	1048-1052	drug	abstract[53]|substance[54]	new[53]|giv[54]	_	_
9-32	1053-1055	as	abstract[53]|substance[54]	new[53]|giv[54]	_	_
9-33	1056-1061	solid	abstract[53]|substance[54]	new[53]|giv[54]	_	_
9-34	1062-1067	lipid	abstract[53]|substance[54]|person	new[53]|giv[54]|new	coref	14-2
9-35	1068-1081	nanoparticles	abstract[53]|substance[54]	new[53]|giv[54]	_	_
9-36	1082-1083	.	_	_	_	_

#Text=The ideal delivery systems of antiepileptic drugs are the ones which provide localized and controlled drug release to targeted sites in the brain , which helps to reduce drug-associated toxicities and enhances the efficacy of the drug .
10-1	1084-1087	The	object[57]	new[57]	coref	10-9[59_57]
10-2	1088-1093	ideal	object[57]	new[57]	_	_
10-3	1094-1102	delivery	abstract|object[57]	new|new[57]	coref	20-14[135_0]
10-4	1103-1110	systems	object[57]	new[57]	_	_
10-5	1111-1113	of	object[57]	new[57]	_	_
10-6	1114-1127	antiepileptic	object[57]|substance[58]	new[57]|giv[58]	coref	17-18[114_58]
10-7	1128-1133	drugs	object[57]|substance[58]	new[57]|giv[58]	_	_
10-8	1134-1137	are	_	_	_	_
10-9	1138-1141	the	object[59]	giv[59]	coref	14-12[92_59]
10-10	1142-1146	ones	object[59]	giv[59]	_	_
10-11	1147-1152	which	_	_	_	_
10-12	1153-1160	provide	_	_	_	_
10-13	1161-1170	localized	event[61]	giv[61]	_	_
10-14	1171-1174	and	event[61]	giv[61]	_	_
10-15	1175-1185	controlled	event[61]	giv[61]	_	_
10-16	1186-1190	drug	substance|event[61]	giv|giv[61]	coref	10-36[66_0]
10-17	1191-1198	release	event[61]	giv[61]	_	_
10-18	1199-1201	to	event[61]	giv[61]	_	_
10-19	1202-1210	targeted	event[61]|place[62]	giv[61]|new[62]	_	_
10-20	1211-1216	sites	event[61]|place[62]	giv[61]|new[62]	_	_
10-21	1217-1219	in	event[61]|place[62]	giv[61]|new[62]	_	_
10-22	1220-1223	the	event[61]|place[62]|object[63]	giv[61]|new[62]|giv[63]	coref	13-11[0_63]
10-23	1224-1229	brain	event[61]|place[62]|object[63]	giv[61]|new[62]|giv[63]	_	_
10-24	1230-1231	,	_	_	_	_
10-25	1232-1237	which	_	_	_	_
10-26	1238-1243	helps	_	_	_	_
10-27	1244-1246	to	_	_	_	_
10-28	1247-1253	reduce	_	_	_	_
10-29	1254-1269	drug-associated	abstract[64]	new[64]	_	_
10-30	1270-1280	toxicities	abstract[64]	new[64]	_	_
10-31	1281-1284	and	_	_	_	_
10-32	1285-1293	enhances	_	_	_	_
10-33	1294-1297	the	abstract[65]	new[65]	coref	18-10[120_65]
10-34	1298-1306	efficacy	abstract[65]	new[65]	_	_
10-35	1307-1309	of	abstract[65]	new[65]	_	_
10-36	1310-1313	the	abstract[65]|substance[66]	new[65]|giv[66]	_	_
10-37	1314-1318	drug	abstract[65]|substance[66]	new[65]|giv[66]	_	_
10-38	1319-1320	.	_	_	_	_

#Text=Carbamazepine ( CBZ ) is an antiepileptic drug with a narrow therapeutic index , and it is poorly absorbed when taken by the oral route .
11-1	1321-1334	Carbamazepine	substance	new	coref	11-6[69_0]
11-2	1335-1336	(	_	_	_	_
11-3	1337-1340	CBZ	object	new	coref	22-23[153_0]
11-4	1341-1342	)	_	_	_	_
11-5	1343-1345	is	_	_	_	_
11-6	1346-1348	an	substance[69]	giv[69]	ana	12-1[0_69]
11-7	1349-1362	antiepileptic	substance[69]	giv[69]	_	_
11-8	1363-1367	drug	substance[69]	giv[69]	_	_
11-9	1368-1372	with	substance[69]	giv[69]	_	_
11-10	1373-1374	a	substance[69]|abstract[70]	giv[69]|new[70]	ana	11-16[0_70]
11-11	1375-1381	narrow	substance[69]|abstract[70]	giv[69]|new[70]	_	_
11-12	1382-1393	therapeutic	substance[69]|abstract[70]	giv[69]|new[70]	_	_
11-13	1394-1399	index	substance[69]|abstract[70]	giv[69]|new[70]	_	_
11-14	1400-1401	,	_	_	_	_
11-15	1402-1405	and	_	_	_	_
11-16	1406-1408	it	abstract	giv	_	_
11-17	1409-1411	is	_	_	_	_
11-18	1412-1418	poorly	_	_	_	_
11-19	1419-1427	absorbed	_	_	_	_
11-20	1428-1432	when	_	_	_	_
11-21	1433-1438	taken	_	_	_	_
11-22	1439-1441	by	_	_	_	_
11-23	1442-1445	the	event[72]	new[72]	_	_
11-24	1446-1450	oral	event[72]	new[72]	_	_
11-25	1451-1456	route	event[72]	new[72]	_	_
11-26	1457-1458	.	_	_	_	_

#Text=Its oral bioavailability is 75 % , and its maximum achieved plasma concentration is about 4 – 8 h after administration .
12-1	1459-1462	Its	substance|quantity[74]	giv|giv[74]	coref|ana|coref|ana	12-5[75_74]|12-9|12-5[75_74]|12-9
12-2	1463-1467	oral	quantity[74]	giv[74]	_	_
12-3	1468-1483	bioavailability	quantity[74]	giv[74]	_	_
12-4	1484-1486	is	_	_	_	_
12-5	1487-1489	75	quantity[75]	giv[75]	coref	17-14[113_75]
12-6	1490-1491	%	quantity[75]	giv[75]	_	_
12-7	1492-1493	,	quantity[75]	giv[75]	_	_
12-8	1494-1497	and	quantity[75]	giv[75]	_	_
12-9	1498-1501	its	quantity[75]|substance|quantity[78]	giv[75]|giv|new[78]	coref|coref|coref|coref	12-15[80_78]|13-1|12-15[80_78]|13-1
12-10	1502-1509	maximum	quantity[75]|quantity[78]	giv[75]|new[78]	_	_
12-11	1510-1518	achieved	quantity[75]|quantity[78]	giv[75]|new[78]	_	_
12-12	1519-1525	plasma	quantity[75]|substance|quantity[78]	giv[75]|new|new[78]	_	_
12-13	1526-1539	concentration	quantity[75]|quantity[78]	giv[75]|new[78]	_	_
12-14	1540-1542	is	quantity[75]	giv[75]	_	_
12-15	1543-1548	about	quantity[75]|quantity[80]	giv[75]|giv[80]	_	_
12-16	1549-1550	4	quantity[75]|quantity[80]	giv[75]|giv[80]	_	_
12-17	1551-1552	–	quantity[75]|quantity[80]	giv[75]|giv[80]	_	_
12-18	1553-1554	8	quantity[75]|quantity|quantity[80]	giv[75]|new|giv[80]	_	_
12-19	1555-1556	h	quantity[75]|quantity[80]	giv[75]|giv[80]	_	_
12-20	1557-1562	after	quantity[75]|quantity[80]	giv[75]|giv[80]	_	_
12-21	1563-1577	administration	quantity[75]|quantity[80]|event	giv[75]|giv[80]|giv	_	_
12-22	1578-1579	.	_	_	_	_

#Text=Carbamazepine acts through the inactivation of sodium channels , making brain cells less excitable .
13-1	1580-1593	Carbamazepine	substance	giv	coref	16-19
13-2	1594-1598	acts	_	_	_	_
13-3	1599-1606	through	_	_	_	_
13-4	1607-1610	the	event[83]	new[83]	_	_
13-5	1611-1623	inactivation	event[83]	new[83]	_	_
13-6	1624-1626	of	event[83]	new[83]	_	_
13-7	1627-1633	sodium	event[83]|substance|place[85]	new[83]|new|new[85]	_	_
13-8	1634-1642	channels	event[83]|place[85]	new[83]|new[85]	_	_
13-9	1643-1644	,	_	_	_	_
13-10	1645-1651	making	_	_	_	_
13-11	1652-1657	brain	object|object[87]	giv|new[87]	_	_
13-12	1658-1663	cells	object[87]	new[87]	_	_
13-13	1664-1668	less	_	_	_	_
13-14	1669-1678	excitable	_	_	_	_
13-15	1679-1680	.	_	_	_	_

#Text=Solid lipid nanoparticles ( SLNs ) are considered an alternative to colloidal systems like liposome , noisome and polymeric nanoparticles .
14-1	1681-1686	Solid	object[89]	new[89]	coref	14-20[0_89]
14-2	1687-1692	lipid	person|object[89]	giv|new[89]	coref	18-7
14-3	1693-1706	nanoparticles	object[89]	new[89]	_	_
14-4	1707-1708	(	_	_	_	_
14-5	1709-1713	SLNs	abstract	new	coref	15-1
14-6	1714-1715	)	_	_	_	_
14-7	1716-1719	are	_	_	_	_
14-8	1720-1730	considered	_	_	_	_
14-9	1731-1733	an	abstract[91]	new[91]	_	_
14-10	1734-1745	alternative	abstract[91]	new[91]	_	_
14-11	1746-1748	to	abstract[91]	new[91]	_	_
14-12	1749-1758	colloidal	abstract[91]|object[92]	new[91]|giv[92]	_	_
14-13	1759-1766	systems	abstract[91]|object[92]	new[91]|giv[92]	_	_
14-14	1767-1771	like	abstract[91]|object[92]	new[91]|giv[92]	_	_
14-15	1772-1780	liposome	abstract[91]|object[92]|object	new[91]|giv[92]|new	_	_
14-16	1781-1782	,	abstract[91]|object[92]	new[91]|giv[92]	_	_
14-17	1783-1790	noisome	abstract[91]|object[92]	new[91]|giv[92]	_	_
14-18	1791-1794	and	abstract[91]|object[92]	new[91]|giv[92]	_	_
14-19	1795-1804	polymeric	abstract[91]|object[92]	new[91]|giv[92]	_	_
14-20	1805-1818	nanoparticles	abstract[91]|object[92]|object	new[91]|giv[92]|giv	coref	18-6[119_0]
14-21	1819-1820	.	_	_	_	_

#Text=SLNs consist of solid lipids , which act as a stabilizer when dispersed in water in the presence of a surfactant .
15-1	1821-1825	SLNs	object	giv	_	_
15-2	1826-1833	consist	_	_	_	_
15-3	1834-1836	of	_	_	_	_
15-4	1837-1842	solid	object[96]	new[96]	_	_
15-5	1843-1849	lipids	object[96]	new[96]	_	_
15-6	1850-1851	,	_	_	_	_
15-7	1852-1857	which	_	_	_	_
15-8	1858-1861	act	_	_	_	_
15-9	1862-1864	as	_	_	_	_
15-10	1865-1866	a	_	_	_	_
15-11	1867-1877	stabilizer	_	_	_	_
15-12	1878-1882	when	_	_	_	_
15-13	1883-1892	dispersed	_	_	_	_
15-14	1893-1895	in	_	_	_	_
15-15	1896-1901	water	substance	new	_	_
15-16	1902-1904	in	_	_	_	_
15-17	1905-1908	the	abstract[98]	new[98]	_	_
15-18	1909-1917	presence	abstract[98]	new[98]	_	_
15-19	1918-1920	of	abstract[98]	new[98]	_	_
15-20	1921-1922	a	abstract[98]|substance[99]	new[98]|new[99]	_	_
15-21	1923-1933	surfactant	abstract[98]|substance[99]	new[98]|new[99]	_	_
15-22	1934-1935	.	_	_	_	_

#Text=SLN is characterized by its small size ( nano range ) , large surface area , and high drug loading capacity .
16-1	1936-1939	SLN	event	new	ana	16-5
16-2	1940-1942	is	_	_	_	_
16-3	1943-1956	characterized	_	_	_	_
16-4	1957-1959	by	_	_	_	_
16-5	1960-1963	its	event|quantity[102]	giv|new[102]	appos|appos	16-9[104_102]|16-9[104_102]
16-6	1964-1969	small	quantity[102]	new[102]	_	_
16-7	1970-1974	size	quantity[102]	new[102]	_	_
16-8	1975-1976	(	_	_	_	_
16-9	1977-1981	nano	object|quantity[104]	new|giv[104]	coref|coref	22-13[151_104]|22-13[151_104]
16-10	1982-1987	range	quantity[104]	giv[104]	_	_
16-11	1988-1989	)	_	_	_	_
16-12	1990-1991	,	_	_	_	_
16-13	1992-1997	large	quantity[106]	new[106]	_	_
16-14	1998-2005	surface	place|quantity[106]	new|new[106]	_	_
16-15	2006-2010	area	quantity[106]	new[106]	_	_
16-16	2011-2012	,	_	_	_	_
16-17	2013-2016	and	_	_	_	_
16-18	2017-2021	high	abstract[109]	new[109]	ana	17-4[0_109]
16-19	2022-2026	drug	substance|abstract[109]	giv|new[109]	coref	19-2
16-20	2027-2034	loading	quantity|abstract[109]	new|new[109]	_	_
16-21	2035-2043	capacity	abstract[109]	new[109]	_	_
16-22	2044-2045	.	_	_	_	_

#Text=In addition , it improves drug stability and has the ability to improve the oral bioavailability of poorly water-soluble drugs .
17-1	2046-2048	In	_	_	_	_
17-2	2049-2057	addition	_	_	_	_
17-3	2058-2059	,	_	_	_	_
17-4	2060-2062	it	abstract	giv	coref	17-10[112_0]
17-5	2063-2071	improves	_	_	_	_
17-6	2072-2076	drug	abstract[111]	new[111]	_	_
17-7	2077-2086	stability	abstract[111]	new[111]	_	_
17-8	2087-2090	and	_	_	_	_
17-9	2091-2094	has	_	_	_	_
17-10	2095-2098	the	abstract[112]	giv[112]	_	_
17-11	2099-2106	ability	abstract[112]	giv[112]	_	_
17-12	2107-2109	to	_	_	_	_
17-13	2110-2117	improve	_	_	_	_
17-14	2118-2121	the	substance[113]	giv[113]	coref	22-8[149_113]
17-15	2122-2126	oral	substance[113]	giv[113]	_	_
17-16	2127-2142	bioavailability	substance[113]	giv[113]	_	_
17-17	2143-2145	of	substance[113]	giv[113]	_	_
17-18	2146-2152	poorly	substance[113]|substance[114]	giv[113]|giv[114]	_	_
17-19	2153-2166	water-soluble	substance[113]|substance[114]	giv[113]|giv[114]	_	_
17-20	2167-2172	drugs	substance[113]|substance[114]	giv[113]|giv[114]	_	_
17-21	2173-2174	.	_	_	_	_

#Text=Gangurde and Kumar prepared lamotrigine solid lipid nanoparticles with a high efficacy for treatment of epilepsy . Nair et al.
18-1	2175-2183	Gangurde	person	new	_	_
18-2	2184-2187	and	_	_	_	_
18-3	2188-2193	Kumar	person	new	coref	19-12
18-4	2194-2202	prepared	_	_	_	_
18-5	2203-2214	lamotrigine	object	new	_	_
18-6	2215-2220	solid	object[119]	giv[119]	coref	19-3[126_119]
18-7	2221-2226	lipid	person|object[119]	giv|giv[119]	coref	19-4
18-8	2227-2240	nanoparticles	object[119]	giv[119]	_	_
18-9	2241-2245	with	_	_	_	_
18-10	2246-2247	a	abstract[120]	giv[120]	_	_
18-11	2248-2252	high	abstract[120]	giv[120]	_	_
18-12	2253-2261	efficacy	abstract[120]	giv[120]	_	_
18-13	2262-2265	for	abstract[120]	giv[120]	_	_
18-14	2266-2275	treatment	abstract[120]|abstract[121]	giv[120]|new[121]	_	_
18-15	2276-2278	of	abstract[120]|abstract[121]	giv[120]|new[121]	_	_
18-16	2279-2287	epilepsy	abstract[120]|abstract[121]|abstract	giv[120]|new[121]|giv	_	_
18-17	2288-2289	.	_	_	_	_
18-18	2290-2294	Nair	person	new	_	_
18-19	2295-2297	et	_	_	_	_
18-20	2298-2301	al.	_	_	_	_

#Text=prepared carbamazepine solid lipid nanoparticles to improve its therapeutic effect . Kumar et al.
19-1	2302-2310	prepared	_	_	_	_
19-2	2311-2324	carbamazepine	substance	giv	ana	19-8
19-3	2325-2330	solid	object[126]	giv[126]	coref	20-2[131_126]
19-4	2331-2336	lipid	person|object[126]	giv|giv[126]	coref	20-3
19-5	2337-2350	nanoparticles	object[126]	giv[126]	_	_
19-6	2351-2353	to	_	_	_	_
19-7	2354-2361	improve	_	_	_	_
19-8	2362-2365	its	substance|abstract[128]	giv|new[128]	coref|coref	21-10|21-10
19-9	2366-2377	therapeutic	abstract[128]	new[128]	_	_
19-10	2378-2384	effect	abstract[128]	new[128]	_	_
19-11	2385-2386	.	_	_	_	_
19-12	2387-2392	Kumar	person	giv	_	_
19-13	2393-2395	et	_	_	_	_
19-14	2396-2399	al.	_	_	_	_

#Text=prepared solid lipid nanoparticles of methylthioadenosine for the management of neurological conditions via oral delivery .
20-1	2400-2408	prepared	_	_	_	_
20-2	2409-2414	solid	object[131]	giv[131]	coref	21-10[140_131]
20-3	2415-2420	lipid	person|object[131]	giv|giv[131]	coref	21-12
20-4	2421-2434	nanoparticles	object[131]	giv[131]	_	_
20-5	2435-2437	of	object[131]	giv[131]	_	_
20-6	2438-2457	methylthioadenosine	object[131]|substance	giv[131]|new	_	_
20-7	2458-2461	for	_	_	_	_
20-8	2462-2465	the	organization[133]	new[133]	_	_
20-9	2466-2476	management	organization[133]	new[133]	_	_
20-10	2477-2479	of	organization[133]	new[133]	_	_
20-11	2480-2492	neurological	organization[133]|abstract[134]	new[133]|new[134]	_	_
20-12	2493-2503	conditions	organization[133]|abstract[134]	new[133]|new[134]	_	_
20-13	2504-2507	via	organization[133]|abstract[134]	new[133]|new[134]	_	_
20-14	2508-2512	oral	organization[133]|abstract[134]|abstract[135]	new[133]|new[134]|giv[135]	_	_
20-15	2513-2521	delivery	organization[133]|abstract[134]|abstract[135]	new[133]|new[134]|giv[135]	_	_
20-16	2522-2523	.	_	_	_	_

#Text=The objective of the current study was to prepare carbamazepine solid lipid nanoparticles ( CBZ-SLNs ) as a novel and alternative method for other colloidal dispersion carriers .
21-1	2524-2527	The	abstract[136]	new[136]	_	_
21-2	2528-2537	objective	abstract[136]	new[136]	_	_
21-3	2538-2540	of	abstract[136]	new[136]	_	_
21-4	2541-2544	the	abstract[136]|event[137]	new[136]|new[137]	coref	22-1[145_137]
21-5	2545-2552	current	abstract[136]|event[137]	new[136]|new[137]	_	_
21-6	2553-2558	study	abstract[136]|event[137]	new[136]|new[137]	_	_
21-7	2559-2562	was	_	_	_	_
21-8	2563-2565	to	_	_	_	_
21-9	2566-2573	prepare	_	_	_	_
21-10	2574-2587	carbamazepine	animal|object[140]	giv|giv[140]	appos|appos	21-15[0_140]|21-15[0_140]
21-11	2588-2593	solid	object[140]	giv[140]	_	_
21-12	2594-2599	lipid	person|object[140]	giv|giv[140]	_	_
21-13	2600-2613	nanoparticles	object[140]	giv[140]	_	_
21-14	2614-2615	(	_	_	_	_
21-15	2616-2624	CBZ-SLNs	object	giv	_	_
21-16	2625-2626	)	_	_	_	_
21-17	2627-2629	as	_	_	_	_
21-18	2630-2631	a	_	_	_	_
21-19	2632-2637	novel	_	_	_	_
21-20	2638-2641	and	_	_	_	_
21-21	2642-2653	alternative	_	_	_	_
21-22	2654-2660	method	_	_	_	_
21-23	2661-2664	for	_	_	_	_
21-24	2665-2670	other	object[144]	new[144]	_	_
21-25	2671-2680	colloidal	object|object[144]	new|new[144]	_	_
21-26	2681-2691	dispersion	abstract|object[144]	new|new[144]	_	_
21-27	2692-2700	carriers	object[144]	new[144]	_	_
21-28	2701-2702	.	_	_	_	_

#Text=The study aimed to prepare CBZ-SLNs with high entrapment efficiency % , small particle size , and high anticonvulsant activity compared to free CBZ .
22-1	2703-2706	The	event[145]	giv[145]	_	_
22-2	2707-2712	study	event[145]	giv[145]	_	_
22-3	2713-2718	aimed	_	_	_	_
22-4	2719-2721	to	_	_	_	_
22-5	2722-2729	prepare	_	_	_	_
22-6	2730-2738	CBZ-SLNs	substance[146]	new[146]	_	_
22-7	2739-2743	with	substance[146]	new[146]	_	_
22-8	2744-2748	high	substance[146]|quantity[149]	new[146]|giv[149]	_	_
22-9	2749-2759	entrapment	substance[146]|quantity|quantity[149]	new[146]|new|giv[149]	_	_
22-10	2760-2770	efficiency	substance[146]|abstract|quantity[149]	new[146]|new|giv[149]	_	_
22-11	2771-2772	%	substance[146]|quantity[149]	new[146]|giv[149]	_	_
22-12	2773-2774	,	substance[146]	new[146]	_	_
22-13	2775-2780	small	substance[146]|quantity[151]	new[146]|giv[151]	_	_
22-14	2781-2789	particle	substance[146]|object|quantity[151]	new[146]|new|giv[151]	_	_
22-15	2790-2794	size	substance[146]|quantity[151]	new[146]|giv[151]	_	_
22-16	2795-2796	,	substance[146]	new[146]	_	_
22-17	2797-2800	and	substance[146]	new[146]	_	_
22-18	2801-2805	high	substance[146]|abstract[152]	new[146]|new[152]	_	_
22-19	2806-2820	anticonvulsant	substance[146]|abstract[152]	new[146]|new[152]	_	_
22-20	2821-2829	activity	substance[146]|abstract[152]	new[146]|new[152]	_	_
22-21	2830-2838	compared	_	_	_	_
22-22	2839-2841	to	_	_	_	_
22-23	2842-2846	free	object[153]	giv[153]	_	_
22-24	2847-2850	CBZ	object[153]	giv[153]	_	_
22-25	2851-2852	.	_	_	_	_
